Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note issued to investors on Monday. The firm issued a sell rating on the stock.

Several other research analysts have also recently issued reports on the stock. Maxim Group decreased their price objective on shares of Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th. Roth Mkm reiterated a buy rating and issued a $40.00 price objective on shares of Moleculin Biotech in a report on Friday, April 12th.

Moleculin Biotech Stock Performance

NASDAQ MBRX opened at $3.96 on Monday. Moleculin Biotech has a 52 week low of $3.21 and a 52 week high of $15.75. The company has a 50-day moving average price of $4.31 and a two-hundred day moving average price of $6.56.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Friday, May 10th. The company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($3.59) by $1.57. Equities research analysts expect that Moleculin Biotech will post -8.79 earnings per share for the current fiscal year.

Institutional Trading of Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 15.52% of the stock is owned by institutional investors and hedge funds.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.